期刊文献+

多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂卡利拉嗪的药理作用和临床评价 被引量:4

Pharmacological and clinical evaluation of cariprazine-dopamine D_(2/3) and 5-HT_(1A) receptor partial agonist in the treatment of schizophrenia and major depressive disorder
原文传递
导出
摘要 卡利拉嗪是一种新型的、多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂,主要用于精神分裂症以及双相Ⅰ型情感障碍相关的躁狂急性发作或混合发作的治疗。本品最常见的不良反应为锥体外系症状,如静坐不能、颤动、呕吐和失眠等。本文对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。 Cariprazine is a novel dopamine D3 and D2receptor partial agonist which is indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also a partial agonist at 5-HT1 Areceptor. The most common adverse events were extrapyramidal symptoms,for instance akathisia,tremor,vomiting and insomnia. The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions were reviewed in this paper.
作者 徐磊 李静华 封宇飞 XU Lei LI Jing-hua FENG Yu-fei(School of Life Science and Biopharmaceutics , Shenyang Pharmaceutical University, Shenyang 110016, China Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Beifing lO0730,China Department of Pharmacy,Zhengzhou Central Hospital,Zhengzhou University, Zhcngzhou 450007, China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第3期250-253,共4页 Chinese Journal of New Drugs
关键词 卡利拉嗪 精神分裂症 双相Ⅰ型情感障碍 多巴胺D2/3受体部分激动剂 5-HT1A受体部分激动剂 药理作用 临床评价 cariprazine schizophrenia bipolar Ⅰ disorder dopamine D3 and D2 receptors partial agonist 5-HT1A receptors partial agonist pharmacology clinical evaluation
  • 相关文献

同被引文献32

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部